Lartruvo OverviewOlaratumab (trade name Lartruvo) is a monoclonal antibody developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It will be removed from the US and the European markets in the first half of 2019 due to insufficient proof of its medical advantage (see below "Medical uses"). Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action...
Read more Lartruvo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olaratumab
Recent Lartruvo Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 500mg/50ml, 500mg/50ml(10mg/ml)
NDC Database Records for Lartruvo: (2 results)Sorted by National Drug Code
- 0002-7190 Lartruvo 10 mg/ml Intravenous Injection, Solution by Eli Lilly and Company
- 0002-8926 Lartruvo 10 mg/ml Intravenous Solution by Eli Lilly and Company